No deaths from anaphylaxis were reported. Safety monitoring identified 21 anaphylaxis reports, corresponding to an estimated rate of 11.1 cases per million doses administered 17 (81% ) had a history of allergies or allergic reactions. The most commonly reported non-anaphylaxis allergic reactions included: rash, itchy skin, itchy and scratchy sensations in the throat, and mild respiratory symptoms. From December 14–23, 2020, 1.89 million first doses of Pfizer-BioNTech COVID-19 vaccine were administered. One health outcome in particular that CDC and FDA monitored for was severe allergic reaction, or anaphylaxis. CDC and FDA immediately began safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Pfizer-BioNTech COVID-19 vaccine was authorized by the Food and Drug Administration (FDA) for emergency use in December 2020. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine JAMA 2021 Feb 23 325(8):780-781 doi: 10.1001/jama.2021.0600.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |